Literature DB >> 8852973

Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine.

M R Oliver1, W C Van Voorhis, M Boeckh, D Mattson, R A Bowden.   

Abstract

This case report describes a bone marrow transplant recipient in whom hepatic zygomycosis developed after ingestion of multiple naturopathic medicines. Mucor was isolated from the patient's liver aspirate and from one of the naturopathic medicines. Arbitrary-primed polymerase chain reaction (PCR) analyses were performed on the Mucor isolates from the patient's liver aspirate and from his naturopathic medicine to see if they were genotypically related. Mucor indicus was the species identified in both the patient's liver aspirate and the naturopathic medicine. Arbitrary-primed PCR analysis revealed that these isolates were genotypically identical. We conclude that this bone marrow transplant recipient acquired hepatic mucormycosis from ingestion of a naturopathic medicine containing Mucor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852973     DOI: 10.1093/clinids/22.3.521

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Gastrointestinal mucormycosis: an evolving disease.

Authors:  Brad Spellberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-02

2.  Clinical usefulness of ELISPOT assay on pericardial fluid in a case of suspected tuberculous pericarditis.

Authors:  A Biglino; P Crivelli; E Concialdi; C Bolla; G Montrucchio
Journal:  Infection       Date:  2008-10-14       Impact factor: 3.553

3.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

4.  First case of gastrointestinal mucormycosis in an immunocompromised patient with gallbladder and duodenum involvement.

Authors:  E Lacarrière; L Lacaze; L Schwarz; E Huet; F Lemoine; M Scotté
Journal:  Infection       Date:  2011-07-23       Impact factor: 3.553

5.  Zygomycosis: an emerging fungal infection with new options for management.

Authors:  Carol A Kauffman; Anurag N Malani
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

6.  Apophysomyces elegans: an emerging zygomycete in India.

Authors:  A Chakrabarti; A Ghosh; G S Prasad; J K David; S Gupta; A Das; V Sakhuja; N K Panda; S K Singh; S Das; T Chakrabarti
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

7.  Successful treatment of a necrotizing fasciitis patient caused by Mucor indicus with amphotericin B and skin grafting.

Authors:  Yijin Luo; Fanqin Zeng; Xiaowen Huang; Qun Li; Guozhen Tan; Liyan Xi; Changming Lu; Qing Guo
Journal:  Mycopathologia       Date:  2014-02-26       Impact factor: 2.574

8.  Gastrointestinal mucormycosis--four cases with different risk factors, involving different anatomical sites.

Authors:  Shailendra Lalwani; Mahendran Govindasamy; Manoj Gupta; Fouzia Siraj; Vibha Varma; Naimaish Mehta; Vinay Kumaran; Neelam Mohan; Prem Chopra; Anil Arora; Shyam Agarwal; Arvinder Soin; Samiran Nundy
Journal:  Indian J Gastroenterol       Date:  2012-06-29

9.  Spectrum of zygomycete species identified in clinically significant specimens in the United States.

Authors:  E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

10.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.